News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinical Trial Of Juno Therapeutics Cell Therapy Restarts


4/21/2014 7:36:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Earlier this month, a study of a much-watched cell therapy that genetically modifies patients’ immune cells in order to attack tumors was stopped because the treatment may have caused the deaths of two patients. The trial is now once again enrolling patients, according to Juno Therapeutics, the startup that is commercializing the treatment. Juno has raised $145 million from investors including Jeff Bezos to develop cancer-fighting cell therapies and is in a race to market with Novartis NVS +0.31%, which made a big bet on a similar technology developed at the University of Pennsylvania, as well as other efforts from Kite Pharma and the team of Bluebird and Celgene CELG -0.23%.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES